



### ウパダシチニブの主な副作用はどのようなものですか？

主な副作用としては、上気道感染（感冒、副鼻腔感染）、悪心、咳嗽、発熱などがあります。この他にもウパダシチニブの副作用が発生する可能性があります。

### ウパダシチニブはどのように服用すればよいですか？

ウパダシチニブは 1 日 1 回の服用です。食前食後は問いません。ウパダシチニブは徐放性の 15 mg 錠です。錠剤を分割したり、潰したり、噛み砕いたりしないでください。担当の医療従事者の指示通りにウパダシチニブを服用してください。

以上がウパダシチニブについて認識しておくべき最も重要な情報です。詳しい情報については、担当の医療従事者にご相談ください。

処方薬の副作用を FDA に報告することが奨励されています。[www.fda.gov/medwatch](http://www.fda.gov/medwatch) をご覧いただくか、1-800-FDA-1088 にお電話ください。

薬剤の支払いが難しい場合は、アッヴィがお手伝いできるかもしれません。詳細については、[AbbVie.com/myAbbVieAssist](http://AbbVie.com/myAbbVieAssist) をご参照ください。

こちらから、ウパダシチニブの詳細な処方情報 (Full Prescribing Information) および服薬ガイド (Medication Guide) についてご参照ください。

世界各国で処方情報は異なります。完全な情報は、各国の製品表示をご参照ください。

### 消化器領域におけるアッヴィについて

潰瘍性大腸炎やクローン病といった炎症性腸疾患 (IBD) の領域を大きく発展させるため、アッヴィは強固な臨床試験プログラムを実施し、最先端の研究に取り組んでいます。革新と学習、そして適応を通して、IBD による患者さんの負担をなくし、患者さんの生活を長期的にわたって改善していくことを目指しています。消化管領域におけるアッヴィについて、詳細は[こちら](#)をご覧ください。

### アッヴィについて

アッヴィのミッションは現在の深刻な健康課題を解決する革新的な医薬品の創製と提供、そして未来に向けて医療上の困難な課題に挑むことです。患者さん一人ひとりの人生を豊かなものにするため次の主要領域に取り組んでいます。免疫疾患、がん、神経疾患、アイケア、ウイルス、ウイメンズヘルス、消化器疾患、さらにアラガンエステティクスポートフォリオの製品・サービスです。アッヴィの詳細については、[www.abbvie.com](http://www.abbvie.com) をご覧ください。Twitter アカウント [@abbvie](#)、[Facebook](#)、[LinkedIn](#) や [Instagram](#) でも情報を公開しています。



## Forward-Looking Statements

Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions, among others, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Such risks and uncertainties include, but are not limited to, failure to realize the expected benefits from AbbVie's acquisition of Allergan plc ("Allergan"), failure to promptly and effectively integrate Allergan's businesses, competition from other products, challenges to intellectual property, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry and the impact of public health outbreaks, epidemics or pandemics, such as COVID-19. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2020 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its subsequent Quarterly Reports on Form 10-Q. AbbVie undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

- 
1. AbbVie. Data on File: ABVRRTI73267.
  2. Cohen S., et al. Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme. *Ann Rheum Dis*. 2020 Oct 28;80(3):304-11.
  3. Mease, P.J., et al. Upadacitinib in Patients with Psoriatic Arthritis and Inadequate Response to Biologics: 56-Week Data from the Randomized Controlled Phase 3 SELECT-PsA 2 Study. *Rheumatol Ther*. 2021 Apr 28. doi: 10.1007/s40744-021-00305-z. Online ahead of print.
  4. Guttman-Yassky E., et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate, double-blind, randomized controlled phase 3 studies. *Lancet*. doi:10.1016/s0140-6736(21)00588-2.
  5. Van der Heijde, D., et al. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial. *Lancet*. 2019 Dec 7;394(10214):2108-2117. doi: 10.1016/S0140-6736(19)32534-6. Epub 2019 Nov 12.
  6. RINVOQ [Summary of Product Characteristics]. AbbVie Deutschland GmbH & Co. KG; September 2021. Available at: [https://www.ema.europa.eu/en/documents/product-information/rinvoq-epar-product-information\\_en.pdf](https://www.ema.europa.eu/en/documents/product-information/rinvoq-epar-product-information_en.pdf).
  7. Pipeline – Our Science | AbbVie. AbbVie. 2021. Available at: <https://www.abbvie.com/our-science/pipeline.html>. Accessed on November 9, 2021.
  8. A Study to Evaluate Efficacy and Safety of Upadacitinib in Adult Participants With Axial Spondyloarthritis (SELECT AXIS 2). *ClinicalTrials.gov*. 2021. Available at: <https://clinicaltrials.gov/ct2/show/NCT04169373>. Accessed on November 9, 2021.
  9. A Study to Evaluate the Safety and Efficacy of ABT-494 for Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis. *ClinicalTrials.gov*. 2021. Available at: <https://clinicaltrials.gov/ct2/show/NCT02819635>. Accessed on November 9, 2021.
  10. A Study to Compare Safety and Efficacy of Upadacitinib to Dupilumab in Adult Participants With Moderate to Severe Atopic Dermatitis (Heads Up). *ClinicalTrials.gov*. 2021. Available at: <https://clinicaltrials.gov/ct2/show/NCT03738397>. Accessed on November 9, 2021.



11. A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Ulcerative Colitis (U-ACCOMPLISH). ClinicalTrials.gov. 2021. Available at: <https://clinicaltrials.gov/ct2/show/NCT03653026>. Accessed on November 9, 2021.
12. A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis (SELECT-GCA). ClinicalTrials.gov. 2021. Available at: <https://clinicaltrials.gov/ct2/show/NCT03725202>. Accessed on November 9, 2021.
13. A Study to Evaluate the Efficacy and Safety of Upadacitinib in Subjects With Takayasu Arteritis (TAK) (SELECT-TAK). ClinicalTrials.gov. 2021. Available at: <https://clinicaltrials.gov/ct2/show/NCT04161898>. Accessed on November 9, 2021.
14. A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy. ClinicalTrials.gov. 2021. Available at: <https://clinicaltrials.gov/ct2/show/NCT03345836>. Accessed on November 9, 2021.
15. Kaplan, G. The global burden of IBD: from 2015 to 2025. *Nat Rev Gastroenterol Hepatol*. 2015 Dec;12(12):720-7. doi: 10.1038/nrgastro.2015.150.
16. The Facts about Inflammatory Bowel Diseases. Crohn's & Colitis Foundation of America. 2014. Available at: <https://www.crohnscolitisfoundation.org/sites/default/files/2019-02/Updated%20IBD%20Factbook.pdf>. Accessed on November 9, 2021.
17. Crohn's disease. Symptoms and Causes. Mayo Clinic. 2021. Available at: <https://www.mayoclinic.org/diseases-conditions/crohns-disease/symptoms-causes/syc-20353304>. Accessed on November 9, 2021.
18. The Economic Costs of Crohn's Disease and Ulcerative Colitis. Access Economics Pty Limited. 2007. Available at: <https://www.crohnsandcolitis.com.au/site/wp-content/uploads/Deloitte-Access-Economics-Report.pdf>. Accessed on November 9, 2021.
19. A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional and/or Biologic Therapies. ClinicalTrials.gov. 2021. Available at: <https://clinicaltrials.gov/ct2/show/NCT03345849>. Accessed on November 9, 2021.
20. A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433. ClinicalTrials.gov. 2021. Available at: <https://clinicaltrials.gov/ct2/show/NCT03345823>. Accessed on November 9, 2021.
21. RINVOQ® (upadacitinib) [Package Insert]. North Chicago, Ill.: AbbVie Inc.